Achieve Life Sciences (NASDAQ: ACHV) is a clinical-stage biopharmaceutical company developing cytisinicline, a plant-derived compound, as a smoking cessation treatment. The company generates no product revenue as of the fiscal year ended December 31, 2025, operating entirely on capital raises and interest income while advancing cytisinicline toward commercial launch. Achieve is headquartered in Vancouver, B.C., and is incorporated in Delaware. Research and development expenses were $23.0 million for FY2025 and $22.8 million for FY2024, focused exclusively on the cytisinicline clinical program. General and administrative expenses were $31.9 million in FY2025, up from $16.3 million in FY2024, with $12.3 million of that increase attributed to commercial launch preparation costs. The company holds license agreements with the University of Bristol (milestone obligations up to $4.8 million) and Sopharma AD ($2.0 million milestone obligation). Achieve has no commercial infrastructure in place as of the filing date of March 24, 2026, and carries convertible debt on its balance sheet alongside contingent consideration liabilities.

Revenue model

Pre-revenue clinical-stage company. No product sales as of FY2025. Operations funded through equity offerings, including a June 2025 public offering of 15,000,000 shares at $3.00 per share with accompanying warrants, and interest income from cash and marketable securities holdings.

Products and services

Cytisinicline: a plant-derived alpha4-beta2 nicotinic acetylcholine receptor partial agonist in development as a prescription smoking cessation therapy. Clinical programs include fixed-dose TID regimens (1.5 mg and 3.0 mg) and a declining titration schedule, evaluated in trials including the ORCA-OL study, which completed in September 2025.

Customers and end markets

End market is smoking cessation. Target patients are adult smokers seeking pharmacological cessation support. No commercial customers as of FY2025. Potential future customers include patients, healthcare providers, and payers, though no commercial infrastructure exists as of the filing.

Value-chain role

Drug developer and future commercial marketer. Licenses cytisinicline IP from Sopharma AD and the University of Bristol. Conducts clinical trials through third-party contract research organizations. Plans to build internal commercial infrastructure for cytisinicline launch, including raw material inventory procurement, which was expensed to R&D prior to regulatory approval.

Geographic exposure

Headquartered in Vancouver, B.C., Canada. Incorporated in Delaware. Clinical and commercial development activities are U.S.-focused based on filing disclosures. No international commercial operations described in the excerpts.

Source: SEC 10-K, filed 2026-03-24

Industry: In Vitro & In Vivo Diagnostic Substances Peers: Acurx Pharmaceuticals Inc Dominari Holdings Inc BioCardia Inc Orgenesis Inc. Lisata Therapeutics Inc CASI Pharmaceuticals, Inc (DE) Cyclerion Therapeutics Inc T2 Biosystems, Inc. Tracon Pharmaceuticals, Inc.